Results 1 to 10 of about 3,030,087 (241)

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

New England Journal of Medicine, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +2 more sources

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

Clinical Cancer Research, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al, Blanke, Charles D, Chae, Young Kwang, Chen, Helen X, Fontaine, Annette, Gatalica, Zoran, Giles, Francis J, Hansel, Donna E, Hayward, Jourdain, Kasi, Anup, Korn, W Michael, Kurzrock, Razelle, Matrana, Marc, Mayerson, Edward, McLeod, Christine, Othus, Megan, Patel, Sandip P, Plets, Melissa, Ryan, Christopher W, Shah, Manisha H, Sharon, Elad, Singh, Preet Paul   +21 more
core   +2 more sources

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

International Journal of Molecular Sciences, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +2 more sources

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues

Biomedicines, 2023
Angiogenic factors (AF) promote vascular formation and may thus support neuroendocrine tumour (NET) development. This study aimed to assess AF serum level changes in NET patients treated with prolonged-acting somatostatin analogues (SSAs).
Violetta Rosiek, Ksenia Janas, Beata Kos-Kudła   +2 more
doaj   +1 more source

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2021
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas ...
M. Shah, W. Goldner, A. Benson, E. Bergsland, L. Blaszkowsky, P. Brock, J. Chan, Satya Das, P. Dickson, P. Fanta, T. Giordano, T. Halfdanarson, D. Halperin, Jin He, A. Heaney, M. Heslin, F. Kandeel, A. Kardan, S. Khan, B. Kuvshinoff, C. Lieu, Kimberly J. Miller, V. Pillarisetty, D. Reidy, S. A. Salgado, Shagufta Shaheen, H. Soares, M. Soulen, J. Strosberg, C. Sussman, N. Trikalinos, Nataliya A Uboha, Namrata Vijayvergia, T. Wong, B. Lynn, Cindy Hochstetler   +35 more
semanticscholar   +1 more source

Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)

Biomedicines, 2023
The coronavirus disease-19 (COVID-19) pandemic dramatically impacted oncological patients’ care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated to also be beneficial to ...
Alice Laffi, Lorenzo Gervaso, Oriana D’Ecclesiis, Sara Gandini, Agostino Riva, Rita Passerini, Francesca Spada, Stefania Pellicori, Manila Rubino, Chiara Alessandra Cella, Paola Simona Ravenda, Maria Giulia Zampino, Nicola Fazio   +12 more
doaj   +1 more source

NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance

Endocrine Connections, 2022
Objective: Up to now, serial NETest measurements in individuals assessing the disease course of gastroenteropancreatic neuroendocrine tumors (GEPNETs) at long-term follow-up and treatment response were not studied.
Mark J C van Treijen, Catharina M Korse, Wieke H Verbeek, Margot E T Tesselaar, Gerlof D Valk   +4 more
doaj   +1 more source

Risk of malignancy in adrenal tumors in patients with a history of cancer

Frontiers in Oncology, 2023
PurposeAdrenal gland is a common site of metastasis and on the other hand, metastases are the most frequent malignant adrenal tumors. The aim of this study was to estimate the risk of malignancy in suspicious adrenal mass in patients with a history of ...
Radosław Samsel, Karolina Nowak, Lucyna Papierska, Edyta Karpeta, Edyta Karpeta, Katarzyna Roszkowska-Purska, Wacław Smiertka, Tomasz Ostrowski, Eryk Chrapowicki, Alan Grabowski, Dorota Leszczyńska, Andrzej Cichocki   +11 more
doaj   +1 more source

The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK

BMC Gastroenterology, 2020
Background NETest, a novel multi-gene liquid biopsy has utility in neuroendocrine tumor (NET) diagnosis and identification of residual disease. We independently assessed utility of the NETest to diagnose gastric neuroendocrine neoplasms (GNENs) and ...
A. Malczewska, A. Procner, A. Walter, K. Kusnierz, W. Zajecki, H. Aslanian, B. Kos-Kudla   +6 more
doaj   +1 more source

Updates on medical treatment for neuroendocrine neoplasm [PDF]

Zhongguo aizheng zazhi, 2022
Neuroendocrine neoplasm (NEN) is a group of heterogeneous malignancies arising from neuroendocrine cells and peptidergic neurons. According to its cell differentiation, NEN can be divided into two distinct groups as well-differentiated neuroendocrine ...
LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie
doaj   +1 more source